Table 1.
Effect of treatment on soluble protein and peptide content, yield, and angiotensin I-converting enzyme (ACE) IC50 of C. sorokiniana protein hydrolysates.
| Sample | Soluble Protein (mg/g) | Peptide Content (mg/g) | Yield 1 | IC50 2 (mg/mL) |
|---|---|---|---|---|
| HWE 3 | 379.9 ± 1.5 | 179.7 ± 2.1 | 4.0 | 1.070 ± 0.020 |
| PX-1 4 | 482.0 ± 2.2 | 260.4 ± 2.0 | 19.1 | 0.043 ± 0.001 |
| PX-2 5 | 566.6 ± 3.5 | 298.6 ± 2.0 | 22.7 | 0.043 ± 0.002 |
| PN-1 6 | 574.8 ± 2.3 | 332.8 ± 3.0 | 28.1 | 0.035 ± 0.002 |
| PN-2 7 | 610.6 ± 3.8 | 341.6 ± 3.1 | 31.2 | 0.042 ± 0.001 |
Each value represents the average of three samples. 1 Yield: (1-dry weight of sample after treatment/dry weight of sample) × 100%. 2 The concentration of an inhibitor required to inhibit 50% of ACE activity. 3 HWE: the hot water extract of C. sorokiniana. 4 PX-1: hydrolysate from Protamex hydrolysis at 1% (the enzyme-to-protein ratio was 1: 100 w/w) for 5 h. 5 PX-2: hydrolysate from Protamex hydrolysis at 2% (the enzyme-to-protein ratio was 2:100 w/w) for 5 h. 6 PN-1: hydrolysate from protease N hydrolysis at 1% (the enzyme-to-protein ratio was 1:100 w/w) for 5 h. 7 PN-2: hydrolysate from protease N hydrolysis at 2% (the enzyme-to-protein ratio was 2:100 w/w) for 5 h.